Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.

June 26 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Under the deal ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bull’s thesis on NVO.

(Reuters) -Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk, arguing that Hims & Hers is abusing compounding as a loophole to bypass its patent, terminated the sales agreement.

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

View images from the Ulla Johnson Resort 2026 Collection.

View photos of the Rebecca Vallance Bridal Fall 2025 collection.

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years.